S&P 500   4,075.28 (-0.12%)
DOW   34,382.33 (-0.60%)
QQQ   293.11 (-0.09%)
AAPL   148.02 (+-0.01%)
MSFT   254.17 (-0.38%)
META   119.89 (+1.52%)
GOOGL   101.04 (+0.05%)
AMZN   95.49 (-1.09%)
TSLA   194.56 (-0.07%)
NVDA   171.48 (+1.33%)
NIO   12.21 (-4.46%)
BABA   86.09 (-1.68%)
AMD   76.83 (-1.03%)
T   19.13 (-0.78%)
MU   55.31 (-4.06%)
CGC   3.76 (+3.87%)
F   14.02 (+0.86%)
GE   85.15 (-0.95%)
DIS   97.93 (+0.06%)
AMC   8.79 (+21.58%)
PYPL   78.22 (-0.24%)
PFE   50.82 (+1.38%)
NFLX   316.76 (+3.68%)
S&P 500   4,075.28 (-0.12%)
DOW   34,382.33 (-0.60%)
QQQ   293.11 (-0.09%)
AAPL   148.02 (+-0.01%)
MSFT   254.17 (-0.38%)
META   119.89 (+1.52%)
GOOGL   101.04 (+0.05%)
AMZN   95.49 (-1.09%)
TSLA   194.56 (-0.07%)
NVDA   171.48 (+1.33%)
NIO   12.21 (-4.46%)
BABA   86.09 (-1.68%)
AMD   76.83 (-1.03%)
T   19.13 (-0.78%)
MU   55.31 (-4.06%)
CGC   3.76 (+3.87%)
F   14.02 (+0.86%)
GE   85.15 (-0.95%)
DIS   97.93 (+0.06%)
AMC   8.79 (+21.58%)
PYPL   78.22 (-0.24%)
PFE   50.82 (+1.38%)
NFLX   316.76 (+3.68%)
S&P 500   4,075.28 (-0.12%)
DOW   34,382.33 (-0.60%)
QQQ   293.11 (-0.09%)
AAPL   148.02 (+-0.01%)
MSFT   254.17 (-0.38%)
META   119.89 (+1.52%)
GOOGL   101.04 (+0.05%)
AMZN   95.49 (-1.09%)
TSLA   194.56 (-0.07%)
NVDA   171.48 (+1.33%)
NIO   12.21 (-4.46%)
BABA   86.09 (-1.68%)
AMD   76.83 (-1.03%)
T   19.13 (-0.78%)
MU   55.31 (-4.06%)
CGC   3.76 (+3.87%)
F   14.02 (+0.86%)
GE   85.15 (-0.95%)
DIS   97.93 (+0.06%)
AMC   8.79 (+21.58%)
PYPL   78.22 (-0.24%)
PFE   50.82 (+1.38%)
NFLX   316.76 (+3.68%)
S&P 500   4,075.28 (-0.12%)
DOW   34,382.33 (-0.60%)
QQQ   293.11 (-0.09%)
AAPL   148.02 (+-0.01%)
MSFT   254.17 (-0.38%)
META   119.89 (+1.52%)
GOOGL   101.04 (+0.05%)
AMZN   95.49 (-1.09%)
TSLA   194.56 (-0.07%)
NVDA   171.48 (+1.33%)
NIO   12.21 (-4.46%)
BABA   86.09 (-1.68%)
AMD   76.83 (-1.03%)
T   19.13 (-0.78%)
MU   55.31 (-4.06%)
CGC   3.76 (+3.87%)
F   14.02 (+0.86%)
GE   85.15 (-0.95%)
DIS   97.93 (+0.06%)
AMC   8.79 (+21.58%)
PYPL   78.22 (-0.24%)
PFE   50.82 (+1.38%)
NFLX   316.76 (+3.68%)
NASDAQ:IDYA

IDEAYA Biosciences - IDYA Stock Forecast, Price & News

$17.74
-0.14 (-0.78%)
(As of 12/1/2022 02:08 PM ET)
Add
Compare
Today's Range
$17.57
▼
$18.05
50-Day Range
$12.02
▼
$18.17
52-Week Range
$8.14
▼
$24.50
Volume
8,203 shs
Average Volume
483,584 shs
Market Capitalization
$853.47 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$28.14

IDEAYA Biosciences MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.86 Rating Score
Upside/​Downside
58.5% Upside
$28.14 Price Target
Short Interest
Bearish
10.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.77
Upright™ Environmental Score
News Sentiment
0.62mentions of IDEAYA Biosciences in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($1.49) to ($2.63) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.02 out of 5 stars

Medical Sector

673rd out of 1,047 stocks

Pharmaceutical Preparations Industry

328th out of 512 stocks

See Top Rated MarketRank™ Stocks Here
IDYA stock logo

About IDEAYA Biosciences (NASDAQ:IDYA) Stock

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, focuses on the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. The company's lead product candidates include IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase I clinical trial for patients with solid tumors having methylthioadenosine phosphorylase deletions; and IDE196, a protein kinase C inhibitor that is in Phase I/II clinical trial for genetically defined cancers having GNAQ or GNA11 gene mutations. Its preclinical pipeline includes various synthetic lethality programs targeting PARG inhibitor in tumors for patients having tumors with a defined biomarker based on genetic mutations and/or molecular signatures; Pol Theta inhibitors in tumors with BRCA or other homologous recombination deficiency mutations; and WRN inhibitors in tumors with high microsatellite instability. The company has a research collaboration agreement with Cancer Research UK and the University of Manchester to develop small molecule inhibitors of Poly (ADP-ribose) glycohydrolase; and a clinical trial collaboration and supply agreement with Pfizer Inc. for Phase I/II study in metastatic uveal melanoma, skin melanoma, and other solid tumors, as well as a strategic partnership with GlaxoSmithKline plc. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDYA Stock News Headlines

November 30, 2022 | americanbankingnews.com
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $28.14 Average Price Target from Brokerages
November 29, 2022 | finance.yahoo.com
IDEAYA Biosciences Announces Agenda Topics and Key Opinion Leader Presenters for Investor R&D Day Webcast on Monday, December 12, 2022
November 28, 2022 | markets.businessinsider.com
IDEAYA Biosciences Appoints Darrin Beaupre As Chief Medical Officer
November 21, 2022 | americanbankingnews.com
Robert W. Baird Raises IDEAYA Biosciences (NASDAQ:IDYA) Price Target to $24.00
November 16, 2022 | finance.yahoo.com
Wall Street Analysts Think IDEAYA Biosciences, Inc. (IDYA) Could Surge 32%: Read This Before Placing a Bet
November 10, 2022 | finance.yahoo.com
IDEAYA Biosciences Third Quarter 2022 Earnings: Beats Expectations
November 8, 2022 | finance.yahoo.com
IDEAYA Biosciences, Inc. (IDYA) Q3 Earnings and Revenues Beat Estimates
November 8, 2022 | finance.yahoo.com
IDEAYA Biosciences, Inc. Reports Third Quarter 2022 Financial Results and Provides Business Update
November 1, 2022 | finance.yahoo.com
IDEAYA Biosciences Announces Plans for Investor R&D Day and Participation in Upcoming Investor Conferences
October 18, 2022 | finance.yahoo.com
Here's Why We're Not Too Worried About IDEAYA Biosciences' (NASDAQ:IDYA) Cash Burn Situation
October 18, 2022 | finance.yahoo.com
IDEAYA Announces Phase 2 MAT2A Inhibitor, IDE397, Achieves First-Patient-In for Multiple Combination Cohorts in MTAP-Deletion Tumors
October 8, 2022 | reuters.com
IDEAYA Biosciences Inc
October 6, 2022 | seekingalpha.com
Ideaya Biosciences: Prospects Rebound With Updated Uveal Melanoma Data
September 21, 2022 | finance.yahoo.com
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) has caught the attention of institutional investors who hold a sizeable 50% stake
September 15, 2022 | nasdaq.com
IDEAYA Biosciences Drops 10% After Pricing Public Offering Of Shares
September 15, 2022 | marketwatch.com
IDEAYA Biosciences Shares Fall Premarket After Public Offering >IDYA
September 15, 2022 | markets.businessinsider.com
IDEAYA Biosciences Prices Underwritten Public Offering Of 7.62 Mln Shares At $10.50/shr
September 13, 2022 | markets.businessinsider.com
Where IDEAYA Biosciences Stands With Analysts
September 12, 2022 | marketwatch.com
IDEAYA Biosciences Shares Surge on Positive Study Data >IDYA
September 12, 2022 | nasdaq.com
IDEAYA Biosciences Rallies 14% On Positive Study Results From Its Uveal Melanoma Drug Candidate
September 12, 2022 | seekingalpha.com
Ideaya says uveal melanoma candidate shrank tumor in 89% of patients
September 11, 2022 | finance.yahoo.com
IDEAYA Reports Positive Interim Phase 2 Clinical Results for Darovasertib and Crizotinib Synthetic Lethal Combination in Metastatic Uveal Melanoma
September 6, 2022 | msn.com
IDEAYA Shares Climb As Initial Stage Uveal Melanoma Study Kick-off In Australia
August 30, 2022 | finance.yahoo.com
IDEAYA Biosciences to Participate in Investor Conferences in September 2022
August 29, 2022 | nasdaq.com
IDEAYA Reports Preclinical Development Milestone In Ongoing IND-enabling Studies With GSK
See More Headlines
Receive IDYA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for IDEAYA Biosciences and its competitors with MarketBeat's FREE daily newsletter.

IDYA Company Calendar

Last Earnings
11/15/2021
Today
12/01/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/21/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:IDYA
CUSIP
N/A
CIK
1676725
Web
www.ideayabio.com
Phone
(650) 443-6209
Fax
N/A
Employees
81
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$28.14
High Stock Price Forecast
$46.00
Low Stock Price Forecast
$13.00
Forecasted Upside/Downside
+58.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.86
Research Coverage
7 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($1.36)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-49,760,000.00
Net Margins
-105.60%
Pretax Margin
-105.60%
Return on Equity
-17.15%
Return on Assets
-14.15%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
12.02
Quick Ratio
12.02

Sales & Book Value

Annual Sales
$27.94 million
Price / Sales
30.55
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$7.66 per share
Price / Book
2.32

Miscellaneous

Outstanding Shares
48,110,000
Free Float
45,707,000
Market Cap
$853.47 million
Optionable
Not Optionable
Beta
0.99

Key Executives

  • Mr. Yujiro S. Hata (Age 48)
    Co-Founder, CEO, Pres & Director
    Comp: $798.72k
  • Mr. Paul A. StoneMr. Paul A. Stone (Age 58)
    Sr. VP, CFO & Principal Accounting Officer
    Comp: $551.44k
  • Dr. Michael A. White Ph.D. (Age 57)
    Sr. VP & Chief Scientific Officer
    Comp: $261k
  • Dr. Jeffrey Hager Ph.D. (Age 58)
    Co-Founder & Member of the Scientific Advisory Board
  • Mr. Andres Ruiz Briseno CPA (Age 36)
    VP and Head of Bus. Operations & IR
  • Mr. Jason S. Throne J.D. (Age 50)
    Esq., Sr. VP, Gen. Counsel & Company Sec.
  • Dr. Paul A. Barsanti Ph.D.
    Sr. VP & Head of Drug Discovery
  • Dr. Matthew Maurer M.D.
    VP and Head of Medical Affairs & Clinical Oncology
  • Mr. Mick O'Quigley
    Sr. VP of Devel. Operations

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions













IDYA Stock - Frequently Asked Questions

Should I buy or sell IDEAYA Biosciences stock right now?

7 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for IDEAYA Biosciences in the last twelve months. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" IDYA shares.
View IDYA analyst ratings or view top-rated stocks.

What is IDEAYA Biosciences' stock price forecast for 2023?

7 brokerages have issued 1-year price objectives for IDEAYA Biosciences' stock. Their IDYA share price forecasts range from $13.00 to $46.00. On average, they predict the company's share price to reach $28.14 in the next year. This suggests a possible upside of 58.8% from the stock's current price.
View analysts price targets for IDYA or view top-rated stocks among Wall Street analysts.

How have IDYA shares performed in 2022?

IDEAYA Biosciences' stock was trading at $23.64 on January 1st, 2022. Since then, IDYA stock has decreased by 25.0% and is now trading at $17.72.
View the best growth stocks for 2022 here.

When is IDEAYA Biosciences' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 21st 2023.
View our IDYA earnings forecast.

How were IDEAYA Biosciences' earnings last quarter?

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) issued its quarterly earnings results on Monday, November, 15th. The company reported ($0.31) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.30) by $0.01. The company earned $8.98 million during the quarter, compared to analyst estimates of $9.49 million. IDEAYA Biosciences had a negative net margin of 105.60% and a negative trailing twelve-month return on equity of 17.15%.

What other stocks do shareholders of IDEAYA Biosciences own?

Based on aggregate information from My MarketBeat watchlists, some companies that other IDEAYA Biosciences investors own include Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), OPKO Health (OPK), Sorrento Therapeutics (SRNE), VBI Vaccines (VBIV), Boeing (BA), Xeris Biopharma (XERS), Entasis Therapeutics (ETTX), Livongo Health (LVGO) and NVIDIA (NVDA).

When did IDEAYA Biosciences IPO?

(IDYA) raised $70 million in an IPO on Thursday, May 23rd 2019. The company issued 5,000,000 shares at a price of $13.00-$15.00 per share. J.P. Morgan, Citigroup and Jefferies served as the underwriters for the IPO.

What is IDEAYA Biosciences' stock symbol?

IDEAYA Biosciences trades on the NASDAQ under the ticker symbol "IDYA."

Who are IDEAYA Biosciences' major shareholders?

IDEAYA Biosciences' stock is owned by many different institutional and retail investors. Top institutional investors include Logos Global Management LP (8.59%), BVF Inc. IL (6.85%), Federated Hermes Inc. (5.95%), BlackRock Inc. (5.56%), Vanguard Group Inc. (4.00%) and State Street Corp (3.95%). Insiders that own company stock include Bvf Partners L P/Il, Jason Throne, Mark Lackner, Michael P Dillon, Michael P Dillon, Paul A Stone, Value Fund L P Biotechnology and Ventures Iv LP 5Am.
View institutional ownership trends.

How do I buy shares of IDEAYA Biosciences?

Shares of IDYA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is IDEAYA Biosciences' stock price today?

One share of IDYA stock can currently be purchased for approximately $17.72.

How much money does IDEAYA Biosciences make?

IDEAYA Biosciences (NASDAQ:IDYA) has a market capitalization of $852.51 million and generates $27.94 million in revenue each year. The company earns $-49,760,000.00 in net income (profit) each year or ($1.36) on an earnings per share basis.

How can I contact IDEAYA Biosciences?

IDEAYA Biosciences' mailing address is 7000 SHORELINE COURT SUITE 350, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.ideayabio.com. The company can be reached via phone at (650) 443-6209 or via email at investor@ideayabio.com.

This page (NASDAQ:IDYA) was last updated on 12/1/2022 by MarketBeat.com Staff